5 results match your criteria: "Guangdong Provincial Clinical Research Centre for Cancer[Affiliation]"
Single-port gasless retroperitoneal laparoscopic adrenalectomy.
Br J Surg
October 2024
State Key Laboratory of Oncology in Southern China, Sun Yat-Sen University Cancer Centre, Guangdong Provincial Clinical Research Centre for Cancer, Collaborative Innovation for Cancer Medicine, Guangzhou, China.
Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial.
J Thorac Oncol
November 2024
Department of Clinical Research, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Centre for Cancer, Guangzhou, People's Republic of China. Electronic address:
Introduction: Patients with anaplastic lymphoma kinase (ALK)-positive NSCLC developing resistance to second-generation inhibitors have limited treatment options. Deulorlatinib is a highly brain-penetrant, new-generation ALK/ROS1 inhibitor. We evaluated the safety, efficacy, and pharmacokinetics of deulorlatinib in ALK-positive NSCLC.
View Article and Find Full Text PDFComparison of long-term quality of life and their predictors in survivors between paediatric and adult nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
BMC Cancer
October 2024
Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Centre, 651 Dongfeng Road East, Guangzhou, 510060, P. R. China.
Article Synopsis
- The study aimed to compare the long-term quality of life (QoL) between survivors of nasopharyngeal carcinoma (NPC) who were children versus adults, and to identify clinical factors influencing QoL.
- A total of 420 NPC survivors (195 paediatric and 225 adult) participated, all having survived at least 8 years post-treatment with intensity-modulated radiotherapy (IMRT).
- Results indicated that paediatric survivors reported better QoL scores across several areas, such as global health, physical function, and social function, but had lower cognitive function compared to adults; different clinical factors were linked to QoL in each group.*
Chronic myeloid leukaemia: Biology and therapy.
Blood Rev
May 2024
Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. Electronic address:
Article Synopsis
- Chronic myeloid leukaemia (CML) is primarily driven by the genetic abnormality BCR::ABL1, and the standard first-line treatment involves tyrosine kinase inhibitors (TKIs).
- Various health organizations have set benchmarks to assess how well patients respond to initial TKI therapy and when to consider switching medications.
- Achieving treatment-free remission (TFR) is now viewed as the ideal outcome, but debates continue over the best initial TKI choice and the required depth and duration of molecular remission for TFR success.
Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial.
Nat Commun
January 2024
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, Guangzhou, China.
Article Synopsis
- Patients with leftover nasopharyngeal carcinoma after treatment have a poor outlook; this trial tested a combination of toripalimab (an anti-PD1 antibody) and capecitabine.
- Out of 23 patients treated, 56.5% achieved complete response, and the overall response rate was 95.7%, meeting the trial's main goal.
- While most patients experienced side effects—mainly hand-foot syndrome—these were manageable, and no severe treatment-related adverse events occurred.